The practical solution is dietary
A review of clinical trial data and real-world evidence has not identified memory impairment as a recognised adverse effect of GLP-1 receptor agonists
Updated July 2026 The Ozempic and GLP-1 gastroparesis lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about the potential risk of developing gastroparesis (i.e., stomach paralysis or delayed gastric emptying), a serious gastrointestinal injury that can cause persistent nausea, vomiting, abdominal pain, bloating, dehydration, malnutrition, hospitalization, or the need for feeding tubes or other invasive treatment
If constipation develops during semaglutide therapy, notify your doctor promptly so adjustments can be made
[DOI] [PubMed] [Google Scholar] 21.Campos RV, Lee YC, Drucker DJ